Shield Therapeutics (STX) News Today GBX 2.35 0.00 (0.00%) As of 11:40 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5BJanuary 13, 2025 | markets.businessinsider.comHardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakevenNovember 21, 2024 | markets.businessinsider.comShield Therapeutics plc (SHIEF)November 17, 2024 | finance.yahoo.comShield Therapeutics reports steady Q3 growth and financial plansOctober 31, 2024 | uk.investing.comShield Therapeutics lines up $15m finance deal and cost saving planOctober 30, 2024 | msn.comInsider Buyers At Shield Therapeutics Recover Some Losses, But Still Down US$28kOctober 16, 2024 | finance.yahoo.comShield Therapeutics: Strong Accrufer Sales Growth Amidst Rising Costs and Market Penetration ChallengesSeptember 26, 2024 | markets.businessinsider.comWhy Zelda: Echoes of Wisdom Doesn't Feature Link as the Main Playable CharacterSeptember 25, 2024 | msn.comShield Therapeutics PLC STX (U.K.: London)September 19, 2024 | wsj.comShield TherapeuticsSeptember 12, 2024 | fool.co.ukShield Therapeutics builds revenues as US prescriptions growSeptember 4, 2024 | msn.comShield Therapeutics to enter Canadian market following approval of iron deficiency drugAugust 28, 2024 | msn.comBoss of drugs firm Shield Therapeutics steps down as US prescriptions ramp upJuly 24, 2024 | msn.comShield Therapeutics CEO Greg Madison To Step DownJuly 24, 2024 | markets.businessinsider.comKorean market is latest play for Shield Therapeutics' iron deficiency drugMay 28, 2024 | msn.comInsider Traders Lose US$91k As Shield Therapeutics DropsMay 9, 2024 | finance.yahoo.comGalera Therapeutics Implements Stockholder Rights Plan to Shield Investor InterestsMay 3, 2024 | msn.comTurning a tumor's 'shield' into a weapon against itselfMay 2, 2024 | msn.comNeutral Switzerland joins European Sky Shield defence projectApril 10, 2024 | msn.comAmerican Home Shield Offering 40% Off ShieldGold™ For Limited TimeApril 1, 2024 | tmcnet.comA Real Life Invisibility Shield for Privacy in Public PlacesMarch 29, 2024 | msn.comSeal Shield to Showcase Shyld AI, the World's First Intelligent, Autonomous, UV-C Disinfection System at HIMSS 2024March 11, 2024 | tmcnet.comLONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutesFebruary 23, 2024 | lse.co.ukShield Therapeutics PLC STXFebruary 22, 2024 | morningstar.comShield Therapeutics plc (STX.L)February 13, 2024 | uk.finance.yahoo.comShield Therapeutics (LON:STX) shareholders have endured a 89% loss from investing in the stock three years agoJanuary 24, 2024 | finance.yahoo.comShield Therapeutics plc (LON:STX) Is Expected To Breakeven In The Near FutureDecember 28, 2023 | finance.yahoo.comShield Therapeutics to present at NPWH conference this monthOctober 20, 2023 | proactiveinvestors.comShield Therapeutics CFO Hans-Peter Rudolf to Step DownOctober 12, 2023 | marketwatch.comShield Therapeutics launches executive search process as CFO steps downOctober 12, 2023 | proactiveinvestors.comShield Therapeutics "couldn't be more pleased" with Viatris collaborationOctober 5, 2023 | finance.yahoo.comShield Therapeutics' pricing will be "key metric" - Proactive Research AnalystOctober 5, 2023 | finance.yahoo.comShield Therapeutics secures debt facility, retail share offer closes soonOctober 3, 2023 | proactiveinvestors.comShield Therapeutics First Half 2023 Earnings: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)September 30, 2023 | finance.yahoo.comShield Therapeutics hails progress in Stateside venture as losses narrowSeptember 29, 2023 | msn.comShield Therapeutics Shares Fall After Discounted Equity RaiseSeptember 28, 2023 | marketwatch.comPrivate companies who hold 41% of Shield Therapeutics plc (LON:STX) gained 17%, institutions profited as wellSeptember 5, 2023 | finance.yahoo.comShield Therapeutics : First signs of hoped-for Accrufer Rx inflectionJuly 29, 2023 | proactiveinvestors.comHardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gatheringJuly 25, 2023 | finanznachrichten.deShield Therapeutics "really starting to fire on all cylinders"July 25, 2023 | finance.yahoo.comShield Therapeutics Shares Rise as US Prescriptions for Accrufer SoarJuly 20, 2023 | marketwatch.comShield Therapeutics makes waves in US as iron deficiency prescriptions ramp upJuly 20, 2023 | msn.comShield Therapeutics reports 173% Accrufer prescription growthJuly 20, 2023 | proactiveinvestors.comSave $30 on the Nvidia Shield Android TV for Amazon Prime DayJuly 11, 2023 | msn.comNeutral Swiss join Europe's Sky Shield defenceJuly 7, 2023 | msn.comSwiss Want In On Germany's Sky Shield PlanJuly 4, 2023 | barrons.comHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptionsMay 17, 2023 | uk.movies.yahoo.comShield Therapeutics directors urge rejection of mandatory offerMay 4, 2023 | proactiveinvestors.comShield Therapeutics well positioned with "great partnership" - Proactive Research AnalystMay 2, 2023 | proactiveinvestors.comShield Therapeutics ready to go full throttle in the USApril 27, 2023 | proactiveinvestors.com Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address STX Media Mentions By Week STX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STX News Sentiment▼0.000.57▲Average Medical News Sentiment STX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STX Articles This Week▼00▲STX Articles Average Week Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VLG News Today EAH News Today CEL News Today CHLL News Today HLN News Today HIK News Today HCM News Today INDV News Today AGY News Today APH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:STX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STX Stock Alerts